Check Out What’s New at Goldfinch

08.10.21

Goldfinch Bio Announces Initiation of Open-Label Extension Study for Patients with Focal Segmental Glomerular Sclerosis (FSGS) Enrolled in Phase 2 Clinical Trial of GFB-887

08.03.21

Goldfinch Bio to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference

07.27.21

Goldfinch Bio Announces Upcoming Presentations at the 13th International Podocyte Conference

06.14.21

Goldfinch Bio to Present at the Raymond James Human Health Innovation Conference

05.13.21

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)